Chemistry:AXS-17
AXS-17, also known as BAER-101 or as AZD-7325, is a GABAA receptor positive allosteric modulator and nonbenzodiazepine which is under development for the treatment of anxiety disorders and absence epilepsy.[1][2][3] It is or was also under development for autism spectrum disorder, fragile X syndrome, and other neurological disorders, but no recent development has been reported for these indications.[2] The drug is a GABAA receptor α2 and α3 subunit-selective partial positive allosteric modulator acting via the benzodiazepine site.[2][1][3] It might have reduced side effects compared to non-selective high-efficacy positive allosteric modulators like the benzodiazepines diazepam and lorazepam.[4] In terms of chemical structure, AXS-17 is a cinnoline derivative.[1] AXS-17 was originated by AstraZeneca and the University College London.[2] It was licensed and under development by Avenue Therapeutics's Baergic Bio, but was later acquired by Axsome Therapeutics, which is now developing the drug.[2][5] As of November 2025, AXS-17 is in phase 2 clinical trials for anxiety disorders and is in the preclinical research stage of development for absence epilepsy.[2] AXS-17 was first described in the scientific literature by at least 2012.[6][4]
See also
References
- ↑ 1.0 1.1 1.2 "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry 63 (7): 3425–3446. April 2020. doi:10.1021/acs.jmedchem.9b01312. PMID 31738537.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "BAER 101". 14 November 2025. https://adisinsight.springer.com/drugs/800027606.
- ↑ 3.0 3.1 "BAER-101, a selective potentiator of α2- and α3-containing GABAA receptors, fully suppresses spontaneous cortical spike-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg (GAERS)". Drug Development Research 85 (2). April 2024. doi:10.1002/ddr.22160. PMID 38380694.
- ↑ 4.0 4.1 "The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males". British Journal of Clinical Pharmacology 78 (6): 1298–1314. December 2014. doi:10.1111/bcp.12413. PMID 24802722.
- ↑ "Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition". 6 November 2025. https://www.fiercebiotech.com/biotech/axsome-adds-astrazeneca-epilepsy-candidate-pipeline-through-avenue-subsidiary-acquisition.
- ↑ "A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison". British Journal of Clinical Pharmacology 74 (1): 98–108. July 2012. doi:10.1111/j.1365-2125.2011.04155.x. PMID 22122233.
 |  |
